Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870398 | 0.88 | PDE9A (0.60) | PDE9APDE1C | |
| SCHEMBL6898925 | 0.88 | PDE9A (0.67) | PDE9APDE1C | |
| Hydrochloric Acid SCHEMBL4511412 | 0.87 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL13865776 | 0.86 | PDE9A (0.58) | PDE9APDE1C | |
| SCHEMBL13865784 | 0.85 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL4510198 | 0.84 | PDE9A (0.56) | PDE9APDE1C | |
| SCHEMBL3725138 | 0.84 | PDE9A (0.56) | PDE9APDE1C | |
| SCHEMBL13865753 | 0.83 | PDE9A (0.57) | PDE9APDE1C | |
| SCHEMBL4498983 | 0.82 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL13866017 | 0.82 | PDE9A (0.59) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011018495-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BDNF, PSEN1, CHRNA5 | PDE9A 349/4885PDE1C 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.